Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trialsJonathan I. Silverberg, Christophe Piketty, Andrew Pink et al.|The Lancet|2024Cited by 144
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week resultsNina Magnolo, Manmath Patekar, Külli Kingo et al.|Journal of the American Academy of Dermatology|2021Cited by 50
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized StudyNina Magnolo, Manmath Patekar, Külli Kingo et al.|Pediatric Drugs|2022Cited by 19
Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigusDario Didona, Michael Hertl, Christoph Hudemann et al.|British Journal of Dermatology|2025Cited by 5